CLINICAL SCIENCE
Chemotherapy and prognosis in advanced thymic carcinoma patients
Zhejiang Cancer Hospital, Department of Medical Oncology, Hangzhou, China.
Read
1089
Timeswas read the article
260
Total PDF
829
Total HTML
Share statistics
array:24 [ "pii" => "S1807593222013059" "issn" => "18075932" "doi" => "10.6061/clinics/2015(12)03" "estado" => "S300" "fechaPublicacion" => "2015-12-01" "aid" => "1305" "copyright" => "CLINICS" "copyrightAnyo" => "2015" "documento" => "article" "crossmark" => 0 "licencia" => "https://creativecommons.org/licenses/by/4.0/" "subdocumento" => "fla" "cita" => "Clinics. 2015;70:775-80" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S1807593222013060" "issn" => "18075932" "doi" => "10.6061/clinics/2015(12)04" "estado" => "S300" "fechaPublicacion" => "2015-12-01" "aid" => "1306" "copyright" => "CLINICS" "documento" => "article" "crossmark" => 0 "licencia" => "https://creativecommons.org/licenses/by/4.0/" "subdocumento" => "fla" "cita" => "Clinics. 2015;70:781-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CLINICAL SCIENCE</span>" "titulo" => "Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "781" "paginaFinal" => "789" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig6" "etiqueta" => "Figure 6" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr6.jpeg" "Alto" => 605 "Ancho" => 800 "Tamanyo" => 42005 ] ] "descripcion" => array:1 [ "en" => "<p id="spara60" class="elsevierStyleSimplePara elsevierViewall">Radiological responses assessed by mRECIST found in the present study compared to other studies in the literature.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Lucas Moretti Monsignore, Jorge Elias-Junior, Valdair Francisco Muglia, Andreza Correa Teixeira, Enio David Mente, Ana de Lourdes Candolo Martinelli, Daniel Giansante Abud" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Lucas Moretti" "apellidos" => "Monsignore" ] 1 => array:2 [ "nombre" => "Jorge" "apellidos" => "Elias-Junior" ] 2 => array:2 [ "nombre" => "Valdair Francisco" "apellidos" => "Muglia" ] 3 => array:2 [ "nombre" => "Andreza Correa" "apellidos" => "Teixeira" ] 4 => array:2 [ "nombre" => "Enio David" "apellidos" => "Mente" ] 5 => array:2 [ "nombre" => "Ana" "apellidos" => "de Lourdes Candolo Martinelli" ] 6 => array:2 [ "nombre" => "Daniel Giansante" "apellidos" => "Abud" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222013060?idApp=UINPBA00004N" "url" => "/18075932/0000007000000012/v1_202212011353/S1807593222013060/v1_202212011353/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1807593222013047" "issn" => "18075932" "doi" => "10.6061/clinics/2015(12)02" "estado" => "S300" "fechaPublicacion" => "2015-12-01" "aid" => "1304" "copyright" => "CLINICS" "documento" => "article" "crossmark" => 0 "licencia" => "https://creativecommons.org/licenses/by/4.0/" "subdocumento" => "fla" "cita" => "Clinics. 2015;70:773-4" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">EDITORIAL</span>" "titulo" => "Building a Lung Transplant Program" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "773" "paginaFinal" => "774" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 564 "Ancho" => 780 "Tamanyo" => 21584 ] ] "descripcion" => array:1 [ "en" => "<p id="spara10" class="elsevierStyleSimplePara elsevierViewall">Kaplan-Meier Survival Curve of LTx patients. One year survival: 65.6%, Five years survival: 55.3% and Ten years survival: 43.7%.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Marcos Naoyuki Samano, Paulo Manuel Pêgo-Fernandes" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Marcos Naoyuki" "apellidos" => "Samano" ] 1 => array:2 [ "nombre" => "Paulo Manuel" "apellidos" => "Pêgo-Fernandes" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222013047?idApp=UINPBA00004N" "url" => "/18075932/0000007000000012/v1_202212011353/S1807593222013047/v1_202212011353/en/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CLINICAL SCIENCE</span>" "titulo" => "Chemotherapy and prognosis in advanced thymic carcinoma patients" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "775" "paginaFinal" => "780" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Zhengbo Song, Xinmin Yu, Yiping Zhang" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Zhengbo" "apellidos" => "Song" ] 1 => array:2 [ "nombre" => "Xinmin" "apellidos" => "Yu" ] 2 => array:4 [ "nombre" => "Yiping" "apellidos" => "Zhang" "email" => array:1 [ 0 => "zjzlyy40@163.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor1" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Zhejiang Cancer Hospital, Department of Medical Oncology, Hangzhou, China." "identificador" => "aff1" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "*" "correspondencia" => "Corresponding author:" ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 431 "Ancho" => 658 "Tamanyo" => 24490 ] ] "descripcion" => array:1 [ "en" => "<p id="spara10" class="elsevierStyleSimplePara elsevierViewall">Kaplan–Meier curves comparing PFS in patients treated with various first-line chemotherapy regimens.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="cesec10" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle60">INTRODUCTION</span><p id="para10" class="elsevierStylePara elsevierViewall">Thymic epithelial tumors are the most common anterior mediastinal neoplasm <a class="elsevierStyleCrossRef" href="#bib1">1</a>. According to worldwide cancer statistics, these tumors are relatively uncommon, with a low incidence of approximately 1.3/1,000,000 people <a class="elsevierStyleCrossRef" href="#bib2">2</a>. According to the histological criteria published by the World Health Organization (WHO) in 2004, they are classified into two histopathological types: thymoma and thymic carcinomas.</p><p id="para20" class="elsevierStylePara elsevierViewall">Thymic carcinomas are rare, invasive thymic epithelial tumors associated with a poor prognosis. Surgery is the main therapeutic modality for early-stage patients <a class="elsevierStyleCrossRef" href="#bib3">3</a>. For people with advanced-stage thymic carcinoma, complete surgical resection is typically not possible, and the only treatment option is palliative chemotherapy or radiochemotherapy <a class="elsevierStyleCrossRef" href="#bib4">4</a>. Despite the 40–60% response rate to first-line chemotherapy of patients with advanced thymic carcinoma, most of these patients relapse within one year of initial treatment and the majority eventually die due to disease progression.</p><p id="para30" class="elsevierStylePara elsevierViewall">Because of the rarity of this cancer, published findings regarding the efficacy and toxicity of chemotherapy are limited. Knowledge regarding chemotherapy for thymic carcinoma has mainly been based on retrospective series with small patient samples, although several prospective trials have also been conducted <a class="elsevierStyleCrossRef" href="#bib4">4</a>. Several studies have described palliative chemotherapy regimens, but because no randomized controlled studies have been performed, it is unclear which regimen is the most effective.</p><p id="para40" class="elsevierStylePara elsevierViewall">Our current study reviewed a series of consecutive patients with advanced thymic carcinoma who had been treated at a single institution to evaluate the efficacies of various regimens. The prognostic factors for advanced thymic carcinoma were also determined.</p></span><span id="cesec20" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle70">MATERIALS AND METHODS</span><span id="cesec30" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle80">Patient eligibility</span><p id="para50" class="elsevierStylePara elsevierViewall">Patients with pathological stage IV (including IVa and IVb) thymic carcinoma who had undergone treatment at Zhejiang Cancer Hospital between January 2000 and December 2012 were retrospectively identified. The study was approved by the Ethics Committee of Zhejiang Cancer Hospital.</p><p id="para60" class="elsevierStylePara elsevierViewall">Two pathologists who were blinded to the patients’ clinical and pathological data reviewed all of the samples. The histologic types were determined based on the 2004 WHO classification <a class="elsevierStyleCrossRef" href="#bib5">5</a>. Patients’ clinical stages were determined according to the Masaoka-Koga staging system <a class="elsevierStyleCrossRef" href="#bib6">6</a>. Histological findings were classified as low-grade (squamous cell, mucoepidermoid, and basaloid carcinomas) or high-grade (lymphoepithelioma-like, neuroendocrine, clear cell, sarcomatoid and undifferentiated carcinomas) according to Suster and Rosai <a class="elsevierStyleCrossRef" href="#bib7">7</a>. Recurrence or metastasis was confirmed by chest CT, bone scan and abdomen CT. Patients who died from another disease not related to thymic carcinoma were excluded from the current study.</p></span><span id="cesec40" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle90">Response evaluation and statistical analysis</span><p id="para70" class="elsevierStylePara elsevierViewall">The Response Evaluation Criteria in Solid Tumors (RECIST 1.1) system was used to evaluate tumor responses. Objective tumor responses included complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). The disease control rate (DCR) was defined as the sum of the objective responses and stabilization rates (CR+PR+SD).</p><p id="para80" class="elsevierStylePara elsevierViewall">Progression-free survival (PFS) encompassed the time from the first cycle of chemotherapy to the time of documented progression or death. Survival was recorded from the first day of treatment to the date of death or that of the last follow-up visit. Survival curves were calculated using the Kaplan–Meier method. Multivariate analysis was performed using the Cox regression model. Statistical analysis was performed with SPSS 17 software (Inc., Chicago, IL). A <span class="elsevierStyleItalic">p</span><0.05 was considered significant. The last follow-up time point was Jan 31, 2014.</p></span></span><span id="cesec50" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle100">RESULTS</span><span id="cesec60" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle110">Patient characteristics</span><p id="para90" class="elsevierStylePara elsevierViewall">A total of 86 patients who met our criteria were identified, and the patient characteristics are listed in <a class="elsevierStyleCrossRef" href="#tbl1">Table 1</a>. The study population consisted of 56 men and 30 women, with a median age at diagnosis of 48 years (range of 31-79). At enrollment, 47 patients (54.7%) had stage IVa disease and 39 (43.3%) had stage IVb disease. Histologic examination revealed the following subtypes of thymic carcinoma: 52 patients (60.5%) had squamous cell carcinoma, 13 (15.1%) had undifferentiated carcinoma, 7 (8.1%) had neuroendocrine carcinoma, 4 (4.7%) had small cell carcinoma, 3 (3.5%) had mucoepidermoid carcinoma and 7 (8.1%) had carcinoma of another subtype. Among the 86 patients, an Eastern Cooperative Oncology Group performance status (PS) of 0–1 was observed in 74 patients (86.0%) and PS 2 (14.0%) was observed in 12 patients.</p><elsevierMultimedia ident="tbl1"></elsevierMultimedia><p id="para100" class="elsevierStylePara elsevierViewall">At the time of treatment, the most common sites of metastasis included the lymph nodes (22 patients, 25.6%), lung (20 patients, 23.3%), liver (14 patients, 16.3%), bone (12 patients, 14.0%) and others (20.8%).</p></span><span id="cesec70" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle120">Chemotherapy regimens</span><p id="para110" class="elsevierStylePara elsevierViewall">The first-line chemotherapy regimens used are shown in <a class="elsevierStyleCrossRef" href="#tbl1">Table 1</a>. The distribution of these regimens was as follows: 7 patients (8.1%) received ADOC (cisplatin, doxorubicin, vincristine and cyclophosphamide); 17 (19.8%) received CAP (cyclophosphamide, doxorubicin, and cisplatin); 12 (14.0%) received VIP (etoposide, ifosfamide and cisplatin); 43 (50.0%) received carboplatin or cisplatin-based doublet chemotherapy (including paclitaxel, gemcitabine, vinorelbine, cyclophosphamide and docetaxel); and 7 (8.1%) received a single agent. Forty-two patients (48.9%) received second-line or greater chemotherapy. The most common regimen was docetaxel-based chemotherapy, which was administered to 16 patients, followed by paclitaxel-based chemotherapy.</p></span><span id="cesec80" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle130">Efficacy analysis of first-line chemotherapy regimens</span><p id="para120" class="elsevierStylePara elsevierViewall">The median follow-up period was 31.5 (5.5-125.0) months. For first-line chemotherapy, 41 patients exhibited a PR (47.7%), 28 showed SD (32.6%) and 17 exhibited PD. There were no complete responders. The response rate for the patients treated with ADOC chemotherapy (n=7) was 42.9% and it was 51.7% for those treated with triplet (CAP and VIP) chemotherapy (n=29), 48.8% for those treated with platinum-based doublet chemotherapy (n=43), and 28.6% for those who received single-agent chemotherapy (n=7) (<a class="elsevierStyleCrossRef" href="#tbl2">Table 2</a>).</p><elsevierMultimedia ident="tbl2"></elsevierMultimedia><p id="para130" class="elsevierStylePara elsevierViewall">The median PFS for all patients was 6.5 months. The PFS values for the ADOC regimen and triplet, doublet and single-agent groups were 7.5 months, 6.6 months, 6.6 months and 2.3 months, respectively (<span class="elsevierStyleItalic">p</span>=0.193) (<a class="elsevierStyleCrossRef" href="#fig1">Figure 1</a>). The median survival time for all patients was 24.1 months (range of 6.5-125 months). The OS values for the ADOC, triplet, doublet and single-agent groups were 27.5 months, 25.4 months, 20.8 months and 8.2 months, respectively (<span class="elsevierStyleItalic">p</span>=0.201) (<a class="elsevierStyleCrossRef" href="#fig2">Figure 2</a>).</p><elsevierMultimedia ident="fig1"></elsevierMultimedia><elsevierMultimedia ident="fig2"></elsevierMultimedia></span><span id="cesec90" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle140">Univariate and Cox regression analyses</span><p id="para140" class="elsevierStylePara elsevierViewall">Univariate analyses were performed using the Kaplan–Meier method to assess the predictive capacity of each variable for the determination of OS and the data are summarized in <a class="elsevierStyleCrossRef" href="#tbl3">Table 3</a>. Gender, age, cancer stage, chemotherapy regimen and smoking status were not found to be significantly associated with OS. PS (<span class="elsevierStyleItalic">p</span>=0.002), histology grade (<span class="elsevierStyleItalic">p</span>=0.020), liver metastasis (<span class="elsevierStyleItalic">p</span>=0.001, <a class="elsevierStyleCrossRef" href="#fig3">Figure 3</a>) and the response to first-line chemotherapy (<span class="elsevierStyleItalic">p</span>=0.047) were predictive of OS.</p><elsevierMultimedia ident="tbl3"></elsevierMultimedia><elsevierMultimedia ident="fig3"></elsevierMultimedia><p id="para150" class="elsevierStylePara elsevierViewall">A multivariate Cox regression model was constructed with the incorporation of PS, histology grade, the response to first-line chemotherapy, cancer stage and liver metastasis to evaluate OS. PS (<span class="elsevierStyleItalic">p</span>=0.043), histology grade (<span class="elsevierStyleItalic">p</span>=0.048) and liver metastasis (<span class="elsevierStyleItalic">p</span>=0.047) remained as independent prognostic factors, but cancer stage (<span class="elsevierStyleItalic">p</span>=0.255) and the response to first-line chemotherapy (<span class="elsevierStyleItalic">p</span>=0.677) did not have significant influences on survival based on multivariate analysis (<a class="elsevierStyleCrossRef" href="#tbl4">Table 4</a>).</p><elsevierMultimedia ident="tbl4"></elsevierMultimedia></span></span><span id="cesec100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle150">DISCUSSION</span><p id="para160" class="elsevierStylePara elsevierViewall">To the best of our knowledge, this is the largest study evaluating the efficacy of chemotherapy and prognostic factors for advanced thymic carcinoma. Our results suggest that there are no differences in efficacy among the different regimens used to treat advanced thymic carcinoma. Liver metastasis, poor PS and high-grade histology indicated a worse prognosis.</p><p id="para170" class="elsevierStylePara elsevierViewall">There is still no consensus on the optimal chemotherapy regimen for advanced thymic carcinoma. Previous studies have shown that multiagent chemotherapy plays an important role in advanced thymic carcinoma <a class="elsevierStyleCrossRef" href="#bib8">8</a>. Anthracycline-based regimens, such as CAP and ADOC, are widely used and are recommended as standard first-line treatments of advanced thymic carcinoma according to the NCCN guidelines. However, the cardiac toxicity of anthracycline-based regimens is an important consideration in clinical practice <a class="elsevierStyleCrossRef" href="#bib9">9</a>,<a class="elsevierStyleCrossRef" href="#bib10">10</a>. Non-anthracycline regimens are preferable to minimize potential cardiac toxicity.</p><p id="para180" class="elsevierStylePara elsevierViewall">The use of platinum-based doublet chemotherapy as first-line chemotherapy has been shown to be efficacious. Regimens such as TC (carboplatin and paclitaxel) and AC (amrubicin and carboplatin) have also been shown to be effective based on studies with small sample sizes <a class="elsevierStyleCrossRefs" href="#bib11">11–15</a>. However, no prospective or retrospective study has compared the efficacies of multiagent and doublet chemotherapy in the treatment of this rare carcinoma. No differences in PFS or OS among the different regimens were observed in the current study; however, the frequency of toxicity was much lower for doublet chemotherapy compared with multiagent chemotherapy (the frequencies of grades 3/4 toxicity were 65.1% and 86.1%, respectively, <span class="elsevierStyleItalic">p</span>=0.06).</p><p id="para190" class="elsevierStylePara elsevierViewall">Few studies have been conducted to identify the prognostic factors for advanced thymic carcinoma. Histologic grade was found to be a significant prognostic factor for overall survival by Hosaka et al. <a class="elsevierStyleCrossRef" href="#bib16">16</a>, but no statistically significant difference was observed between low- and high-grade histology groups in another study <a class="elsevierStyleCrossRef" href="#bib17">17</a>. However, in the present study, a significant difference in OS between the low-grade and high-grade histology groups was observed. A retrospective study conducted by Okuma et al. <a class="elsevierStyleCrossRef" href="#bib17">17</a>, which included 40 advanced thymic carcinoma patients, demonstrated that the response to first-line chemotherapy was the only factor associated with a significantly better prognosis. In contrast, this response was not found to be a significant prognostic factor based on multivariate analysis in the current study. Our results showed that liver metastasis was a poor prognostic factor for advanced thymic carcinoma, consistent with other solid carcinomas <a class="elsevierStyleCrossRef" href="#bib18">18</a>.</p><p id="para200" class="elsevierStylePara elsevierViewall">Recent studies have focused on the role of targeted therapy in advanced thymic carcinoma. c-KIT expression has been demonstrated to be common in thymic carcinomas. Several case reports have documented clinical responses to treatment with sunitinib and sorafenib <a class="elsevierStyleCrossRefs" href="#bib20">19-20</a>. Recently, Rajan et al. <a class="elsevierStyleCrossRef" href="#bib21">21</a> have shown that cixutumumab, a fully human IgG1 monoclonal antibody that targets insulin-like growth factor 1 receptor and is used as a mono-therapy, is well tolerated and is active in patients with relapsed thymoma but not in those with thymic carcinoma.</p><p id="para210" class="elsevierStylePara elsevierViewall">The major limitations of the present study are its retrospective nature and the heterogeneity of the chemotherapy regimens evaluated. However, it provides relevant insights into the efficacies of different treatments of advanced thymic carcinoma as one of the largest reports to date focusing on treatment regimens for this rare tumor type.</p><p id="para220" class="elsevierStylePara elsevierViewall">The results of this study suggest that there is no difference in efficacy between multiagent and doublet regimens (the <span class="elsevierStyleItalic">p</span> values for PFS and OS were 0.93 and 0.63, respectively). The prognosis of advanced thymic carcinoma can be predicted based on histological findings, liver metastasis and PS.</p></span><span id="cesec110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle160">AUTHOR CONTRIBUTIONS</span><p id="para230" class="elsevierStylePara elsevierViewall">Song Z was responsible for collection of the study data and manuscript writing. Yu X was responsible for manuscript writing. Zhang Y was responsible for collection of the study data and the literature review.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:7 [ 0 => array:2 [ "identificador" => "xpalclavsec1582262" "titulo" => "KEYWORDS" ] 1 => array:2 [ "identificador" => "cesec10" "titulo" => "INTRODUCTION" ] 2 => array:3 [ "identificador" => "cesec20" "titulo" => "MATERIALS AND METHODS" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "cesec30" "titulo" => "Patient eligibility" ] 1 => array:2 [ "identificador" => "cesec40" "titulo" => "Response evaluation and statistical analysis" ] ] ] 3 => array:3 [ "identificador" => "cesec50" "titulo" => "RESULTS" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "cesec60" "titulo" => "Patient characteristics" ] 1 => array:2 [ "identificador" => "cesec70" "titulo" => "Chemotherapy regimens" ] 2 => array:2 [ "identificador" => "cesec80" "titulo" => "Efficacy analysis of first-line chemotherapy regimens" ] 3 => array:2 [ "identificador" => "cesec90" "titulo" => "Univariate and Cox regression analyses" ] ] ] 4 => array:2 [ "identificador" => "cesec100" "titulo" => "DISCUSSION" ] 5 => array:2 [ "identificador" => "cesec110" "titulo" => "AUTHOR CONTRIBUTIONS" ] 6 => array:1 [ "titulo" => "REFERENCES" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2015-07-30" "fechaAceptado" => "2015-08-26" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "KEYWORDS" "identificador" => "xpalclavsec1582262" "palabras" => array:3 [ 0 => "Thymic carcinoma" 1 => "Chemotherapy" 2 => "Prognosis" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:2 [ "resumen" => "<span id="ceabs10" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle10">OBJECTIVE:</span><p id="spara80" class="elsevierStyleSimplePara elsevierViewall">The role of chemotherapy in treating advanced thymic carcinoma is unclear. The purpose of the current study was to investigate the efficacy of chemotherapy and the prognostic factors for patients with advanced thymic carcinoma.</p></span> <span id="ceabs20" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle20">METHODS:</span><p id="spara90" class="elsevierStyleSimplePara elsevierViewall">A retrospective review of the medical records of 86 patients treated with chemotherapy for advanced thymic carcinoma was conducted between 2000 and 2012 at our institution. The clinical characteristics, chemotherapy regimens and prognostic factors were analyzed. Survival curves were plotted using the Kaplan–Meier method and the Cox proportional hazard model was used for multivariate analysis.</p></span> <span id="ceabs30" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle30">RESULTS:</span><p id="spara100" class="elsevierStyleSimplePara elsevierViewall">Of the 86 patients, 56 were male and 30 were female. The median survival time was 24.5 months. For the first-line chemotherapy treatment, the objective response rate was 47.7% and the disease control rate was 80.2%. The median progression-free survival for all patients was 6.5 months for first-line chemotherapy. No significant differences in progression-free survival were observed among the different chemotherapy regimens. Multivariate analyses revealed that the prognostic factors for overall survival included performance status (<span class="elsevierStyleItalic">p</span>=0.043), histology grade (<span class="elsevierStyleItalic">p</span>=0.048), and liver metastasis (<span class="elsevierStyleItalic">p</span>=0.047).</p></span> <span id="ceabs40" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle40">CONCLUSION:</span><p id="spara110" class="elsevierStyleSimplePara elsevierViewall">Our results suggest that there is no difference in efficacy between multiagent and doublet regimens. The prognosis of patients with advanced thymic carcinoma can be predicted based on histological grade, liver metastasis and performance status.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "ceabs10" "titulo" => "OBJECTIVE:" ] 1 => array:2 [ "identificador" => "ceabs20" "titulo" => "METHODS:" ] 2 => array:2 [ "identificador" => "ceabs30" "titulo" => "RESULTS:" ] 3 => array:2 [ "identificador" => "ceabs40" "titulo" => "CONCLUSION:" ] ] ] ] "NotaPie" => array:1 [ 0 => array:1 [ "nota" => "<p class="elsevierStyleNotepara" id="cenpara10">No potential conflict of interest was reported.</p>" ] ] "multimedia" => array:7 [ 0 => array:7 [ "identificador" => "fig1" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 431 "Ancho" => 658 "Tamanyo" => 24490 ] ] "descripcion" => array:1 [ "en" => "<p id="spara10" class="elsevierStyleSimplePara elsevierViewall">Kaplan–Meier curves comparing PFS in patients treated with various first-line chemotherapy regimens.</p>" ] ] 1 => array:7 [ "identificador" => "fig2" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 496 "Ancho" => 657 "Tamanyo" => 25627 ] ] "descripcion" => array:1 [ "en" => "<p id="spara20" class="elsevierStyleSimplePara elsevierViewall">Kaplan–Meier curves comparing OS in patients treated with various first-line chemotherapy regimens.</p>" ] ] 2 => array:7 [ "identificador" => "fig3" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 472 "Ancho" => 659 "Tamanyo" => 21673 ] ] "descripcion" => array:1 [ "en" => "<p id="spara30" class="elsevierStyleSimplePara elsevierViewall">Kaplan–Meier curves comparing OS in patients with different histological grades.</p>" ] ] 3 => array:7 [ "identificador" => "tbl1" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="tfn1" class="elsevierStyleSimplePara elsevierViewall">ADOC: cisplatin, doxorubicin, vincristine and cyclophosphamide</p>" "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="bottom" scope="col"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="bottom" scope="col">Number (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Gender \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Male \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">56(65.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Female \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">30(34.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Age \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Range \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">31-79 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Median \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">48 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span><50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">52(60.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>≥50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">34(39.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Smoking status \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Never \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">32(37.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Former/current \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">54(62.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Stage \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>IVa \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">47(54.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>IVb \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">39(45.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Liver metastasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">14(19.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">72(80.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">PS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>0-1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">74(86.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>2-3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">12(14.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Histology \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Low-grade \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">55(64.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Squamous cell carcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">52(60.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Mucoepidermoid carcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">3(4.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>High-grade \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">31(36) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Undifferentiated carcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">13(15.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Neuroendocrine carcinomas \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">7(8.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Small cell carcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">4(4.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Others \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">7(8.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">First-line chemotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>ADOC \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">7(8.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Triplet chemotherapies \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">29(33.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Double regimens \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">43(50.0) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Cisplatin-containing \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">25(29.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Carboplatin-containing \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">18(20.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Single-agent \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">7(8.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Further-line chemotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">42(48.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">44(51.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spara40" class="elsevierStyleSimplePara elsevierViewall">Demographic characteristics of the study population.Demographic characteristics of the study population.</p>" ] ] 4 => array:7 [ "identificador" => "tbl2" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="bottom" scope="col">Efficacy \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col">ADOC (n=7) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col">Triplet (n=29) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col">Doublet (n=43) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col">Single-agent (n=7) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Complete response \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Partial response \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Stable disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Progressive disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Response rate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">42.90% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">51.70% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">48.80% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">28.60% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Disease control rate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">85.70% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">82.80% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">79.10% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">42.90% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">Median progression-free survival \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">7.5 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">6.6 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">6.6 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">2.3 months \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Median overall survival \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">27.5 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">25.4 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">20.8 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="bottom">8.2 months \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spara50" class="elsevierStyleSimplePara elsevierViewall">The efficacy of different regimens.</p>" ] ] 5 => array:7 [ "identificador" => "tbl3" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="bottom" scope="col"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col">Median PFS \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col"><span class="elsevierStyleItalic">p</span> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col">Median OS \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col"><span class="elsevierStyleItalic">p</span> \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Gender \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.650 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.722 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Male \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">6.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">24.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Female \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">5.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">24.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Age \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.059 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.749 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span><50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">6.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">24.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>≥50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">5.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">18.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Smoking status \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.785 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.895 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Never \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">6.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">24.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Former/current \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">6.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">20.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Stage \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.126 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>IVa \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">7.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>IVb \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">5.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">PS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.019 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.002 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>0-1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">6.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">24.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>2-3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">2.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">9.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Histology \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.023 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.020 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Low-grade \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">7.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">25.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>High-grade \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">4.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">14.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleBold">Liver metastasis</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.013 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold">Yes</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">2.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">10.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold">No</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">6.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">25.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">First-line chemotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.193 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.201 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>ADOC \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">7.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">27.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Triplet \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">6.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">25.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Double regimens \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">6.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">20.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Single-agent \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">2.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">8.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Further-line chemotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.725 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.042 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">6.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">27.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">6.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">20.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Response to first-line chemotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.014 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.047 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">8.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">28.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"><span class="elsevierStyleHsp" style=""></span>No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">4.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">21.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spara60" class="elsevierStyleSimplePara elsevierViewall">Univariate analysis of the patient survival according to the clinicopathologic characteristics.</p>" ] ] 6 => array:7 [ "identificador" => "tbl4" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="bottom" scope="col"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="3" align="center" valign="bottom" scope="col">PFS</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="3" align="center" valign="bottom" scope="col">OS</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="bottom" scope="col"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col">HR \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col">95% CI \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col"><span class="elsevierStyleItalic">p</span> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col">HR \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col">95% CI \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="bottom" scope="col"><span class="elsevierStyleItalic">p</span> \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Liver metastasis (yes vs. no) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">2.716 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">1.052-50121 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.027 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">1.757 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">1.214-3.557 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.047 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Histology (Low-grade vs. high-grade) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.489 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.411-0.978 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.032 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.761 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.475-0.996 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.048 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Stage (IVb vs. IVa) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">1.24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.875-3.552 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.127 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">1.987 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.457-5.213 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.255 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">PS (2-3/0-1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">2.756 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">1.542-4.221 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.006 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">2.712 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">1.251-5.512 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.043 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="bottom">Response to first-line chemotherapy (yes vs. no) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.754 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.424-1.572 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.067 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.812 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.517-2.423 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="bottom">0.677 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spara70" class="elsevierStyleSimplePara elsevierViewall">Multivariate survival analysis for disease-Free survival and overall survival.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "REFERENCES" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "cebibsec10" "bibliografiaReferencia" => array:21 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Thymic carcinoma: state of the art review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => """ TY Eng \n \t\t\t\t\t\t\t\t """ 1 => """ CD Fuller \n \t\t\t\t\t\t\t\t """ 2 => """ J Jagirdar \n \t\t\t\t\t\t\t\t """ 3 => """ Y Bains \n \t\t\t\t\t\t\t\t """ 4 => """ CR Thomas Jr \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/j.ijrobp.2003.11.021" "Revista" => array:7 [ "tituloSerie" => "Int J Radiat Oncol Biol Phys" "fecha" => "2004" "volumen" => "59" "numero" => "3" "paginaInicial" => "654" "paginaFinal" => "664" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15183468" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/j.ijrobp.2003.11.021" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/j.ijrobp.2003.11.021" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => """ EA Engels \n \t\t\t\t\t\t\t\t """ 1 => """ RM Pfeiffer \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1002/ijc.11099" "Revista" => array:7 [ "tituloSerie" => "Int J Cancer" "fecha" => "2003" "volumen" => "105" "numero" => "4" "paginaInicial" => "546" "paginaFinal" => "551" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12712448" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1002/ijc.11099" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1002/ijc.11099" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Thymic carcinoma: a cohort study of patients from the european society of thoracic surgeons database" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ E Ruffini \n \t\t\t\t\t\t\t\t """ 1 => """ F Detterbeck \n \t\t\t\t\t\t\t\t """ 2 => """ D Van Raemdonck \n \t\t\t\t\t\t\t\t """ 3 => """ G Rocco \n \t\t\t\t\t\t\t\t """ 4 => """ P Thomas \n \t\t\t\t\t\t\t\t """ 5 => """ W Weder \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1097/JTO.0000000000000128" "Revista" => array:7 [ "tituloSerie" => "J Thorac Oncol" "fecha" => "2014" "volumen" => "9" "numero" => "4" "paginaInicial" => "541" "paginaFinal" => "548" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24736078" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1097/JTO.0000000000000128" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1097/JTO.0000000000000128" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemotherapy for thymic carcinoma and advanced thymoma in adults" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ ML Wei \n \t\t\t\t\t\t\t\t """ 1 => """ D Kang \n \t\t\t\t\t\t\t\t """ 2 => """ L Gu \n \t\t\t\t\t\t\t\t """ 3 => """ M Qiu \n \t\t\t\t\t\t\t\t """ 4 => """ L Zhengyin \n \t\t\t\t\t\t\t\t """ 5 => """ Y Mu \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Cochrane Database Syst Rev" "fecha" => "2013" "volumen" => "8" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "World Health Organization classification of tumours" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ A Marx \n \t\t\t\t\t\t\t\t """ 1 => """ PH Strobel \n \t\t\t\t\t\t\t\t """ 2 => """ A Zettl \n \t\t\t\t\t\t\t\t """ 3 => """ JKC Chan \n \t\t\t\t\t\t\t\t """ 4 => """ HK Müller-Hermelink \n \t\t\t\t\t\t\t\t """ 5 => """ CC Harris \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:4 [ "titulo" => "Pathology and genetics of tumours of the lung, pleura, thymus and heart" "paginaInicial" => "152" "paginaFinal" => "153" "serieFecha" => "2004" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Follow-up study of thymomas with special reference to their clinical stages" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ A Masaoka \n \t\t\t\t\t\t\t\t """ 1 => """ Y Monden \n \t\t\t\t\t\t\t\t """ 2 => """ K Nakahara \n \t\t\t\t\t\t\t\t """ 3 => """ T Tanioka \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1002/1097-0142(19811201)48:11<2485::aid-cncr2820481123>3.0.co;2-r" "Revista" => array:7 [ "tituloSerie" => "Cancer" "fecha" => "1981" "volumen" => "48" "numero" => "11" "paginaInicial" => "2485" "paginaFinal" => "2492" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7296496" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1002/1097-0142(19811201)48:11<2485::aid-cncr2820481123>3.0.co;2-r" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Thymic carcinoma. A clinicopathologic study of 60 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => """ S Suster \n \t\t\t\t\t\t\t\t """ 1 => """ J Rosai \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1002/1097-0142(19910215)67:4<1025::aid-cncr2820670427>3.0.co;2-f" "Revista" => array:7 [ "tituloSerie" => "Cancer" "fecha" => "1991" "volumen" => "67" "numero" => "4" "paginaInicial" => "1025" "paginaFinal" => "1032" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1991250" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1002/1097-0142(19910215)67:4<1025::aid-cncr2820670427>3.0.co;2-f" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1002/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of chemotherapy in advanced thymoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => """ J Schmitt \n \t\t\t\t\t\t\t\t """ 1 => """ PJ Loehrer Sr \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1097/JTO.0b013e3181f21129" "Revista" => array:7 [ "tituloSerie" => "J Thorac Oncol. J Thorac Oncol" "fecha" => "2010" "volumen" => "5" "numero" => "10 Suppl 4" "paginaInicial" => "S357" "paginaFinal" => "S360" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20859133" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1097/JTO.0b013e3181f21129" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1097/JTO.0b013e3181f21129" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemotherapy of invasive thymoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ A Fornasiero \n \t\t\t\t\t\t\t\t """ 1 => """ O Daniele \n \t\t\t\t\t\t\t\t """ 2 => """ C Ghiotto \n \t\t\t\t\t\t\t\t """ 3 => """ F Sartori \n \t\t\t\t\t\t\t\t """ 4 => """ F Rea \n \t\t\t\t\t\t\t\t """ 5 => """ M Piazza \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.1990.8.8.1419" "Revista" => array:7 [ "tituloSerie" => "J Clin Oncol" "fecha" => "1990" "volumen" => "8" "numero" => "8" "paginaInicial" => "1419" "paginaFinal" => "1423" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2380761" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ PJ Loehrer Sr \n \t\t\t\t\t\t\t\t """ 1 => """ K Kim \n \t\t\t\t\t\t\t\t """ 2 => """ SC Aisner \n \t\t\t\t\t\t\t\t """ 3 => """ R Livingston \n \t\t\t\t\t\t\t\t """ 4 => """ LH Einhorn \n \t\t\t\t\t\t\t\t """ 5 => """ D Johnson \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.1994.12.6.1164" "Revista" => array:7 [ "tituloSerie" => "J Clin Oncol" "fecha" => "1994" "volumen" => "12" "numero" => "6" "paginaInicial" => "1164" "paginaFinal" => "1168" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8201378" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ GL Lemma \n \t\t\t\t\t\t\t\t """ 1 => """ JW Lee \n \t\t\t\t\t\t\t\t """ 2 => """ SC Aisner \n \t\t\t\t\t\t\t\t """ 3 => """ CJ Langer \n \t\t\t\t\t\t\t\t """ 4 => """ WJ Tester \n \t\t\t\t\t\t\t\t """ 5 => """ DH Johnson \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1200/JCO.2010.32.9607" "Revista" => array:7 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2011" "volumen" => "29" "numero" => "15" "paginaInicial" => "2060" "paginaFinal" => "2065" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21502559" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1200/JCO.2010.32.9607" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1200/JCO.2010.32.9607" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ GL Lemma \n \t\t\t\t\t\t\t\t """ 1 => """ JW Lee \n \t\t\t\t\t\t\t\t """ 2 => """ SC Aisner \n \t\t\t\t\t\t\t\t """ 3 => """ CJ Langer \n \t\t\t\t\t\t\t\t """ 4 => """ WJ Tester \n \t\t\t\t\t\t\t\t """ 5 => """ DH Johnson \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/j.lungcan.2009.03.031" "Revista" => array:7 [ "tituloSerie" => "Lung Cancer" "fecha" => "2010" "volumen" => "67" "numero" => "15" "paginaInicial" => "194" "paginaFinal" => "197" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19409644" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/j.lungcan.2009.03.031" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/j.lungcan.2009.03.031" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Salvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma—three cases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ Y Komatsu \n \t\t\t\t\t\t\t\t """ 1 => """ T Koizumi \n \t\t\t\t\t\t\t\t """ 2 => """ T Tanabe \n \t\t\t\t\t\t\t\t """ 3 => """ O Hatayama \n \t\t\t\t\t\t\t\t """ 4 => """ M Yasuo \n \t\t\t\t\t\t\t\t """ 5 => """ M Okada \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Anticancer Res" "fecha" => "2006" "volumen" => "26" "numero" => "6C" "paginaInicial" => "4851" "paginaFinal" => "4855" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemotherapy with carboplatin and paclitaxel after failure of primary chemotherapy for advanced thymic carcinoma. A report of three cases and review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ K Watanabe \n \t\t\t\t\t\t\t\t """ 1 => """ M Shinkai \n \t\t\t\t\t\t\t\t """ 2 => """ H Goto \n \t\t\t\t\t\t\t\t """ 3 => """ S Yoshikawa \n \t\t\t\t\t\t\t\t """ 4 => """ N Yamaguchi \n \t\t\t\t\t\t\t\t """ 5 => """ Y Hara \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/030089161309900428" "Revista" => array:7 [ "tituloSerie" => "Tumori" "fecha" => "2013" "volumen" => "99" "numero" => "4" "paginaInicial" => "e172" "paginaFinal" => "e176" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24326856" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ A Inoue \n \t\t\t\t\t\t\t\t """ 1 => """ S Sugawara \n \t\t\t\t\t\t\t\t """ 2 => """ M Harada \n \t\t\t\t\t\t\t\t """ 3 => """ K Kobayashi \n \t\t\t\t\t\t\t\t """ 4 => """ T Kozuki \n \t\t\t\t\t\t\t\t """ 5 => """ S Kuyama \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1097/JTO.0000000000000362" "Revista" => array:7 [ "tituloSerie" => "J Thorac Oncol" "fecha" => "2014" "volumen" => "9" "numero" => "12" "paginaInicial" => "1805" "paginaFinal" => "1809" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25393793" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1097/JTO.0000000000000362" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1097/JTO.0000000000000362" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Masaoka Stage and Histologic Grade Predict Prognosis in Patients With Thymic Carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ Y Hosaka \n \t\t\t\t\t\t\t\t """ 1 => """ M Tsuchida \n \t\t\t\t\t\t\t\t """ 2 => """ S Toyabe \n \t\t\t\t\t\t\t\t """ 3 => """ H Umezu \n \t\t\t\t\t\t\t\t """ 4 => """ T Eimoto \n \t\t\t\t\t\t\t\t """ 5 => """ J Hayashi \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/j.athoracsur.2009.11.057" "Revista" => array:7 [ "tituloSerie" => "Ann Thorac Surg" "fecha" => "2010" "volumen" => "89" "numero" => "3" "paginaInicial" => "912" "paginaFinal" => "917" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20172153" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/j.athoracsur.2009.11.057" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/j.athoracsur.2009.11.057" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical outcomes with chemotherapy for advanced thymic carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ Y Okuma \n \t\t\t\t\t\t\t\t """ 1 => """ Y Hosomi \n \t\t\t\t\t\t\t\t """ 2 => """ Y Takagi \n \t\t\t\t\t\t\t\t """ 3 => """ E Sasaki \n \t\t\t\t\t\t\t\t """ 4 => """ T Hishima \n \t\t\t\t\t\t\t\t """ 5 => """ Y Maeda \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/j.lungcan.2012.12.012" "Revista" => array:7 [ "tituloSerie" => "Lung Cancer" "fecha" => "2013" "volumen" => "80" "numero" => "1" "paginaInicial" => "75" "paginaFinal" => "80" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23313005" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/j.lungcan.2012.12.012" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/j.lungcan.2012.12.012" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => """ T Hoang \n \t\t\t\t\t\t\t\t """ 1 => """ R Xu \n \t\t\t\t\t\t\t\t """ 2 => """ JH Schiller \n \t\t\t\t\t\t\t\t """ 3 => """ P Bonomi \n \t\t\t\t\t\t\t\t """ 4 => """ DH Johnson \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1200/JCO.2005.04.177" "Revista" => array:8 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2005" "volumen" => "23" "numero" => "1" "paginaInicial" => "175" "paginaFinal" => "183" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15625371" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1059131118303698" "estado" => "S300" "issn" => "10591311" ] ] ] 1 => array:2 [ "doi" => "10.1200/JCO.2005.04.177" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1200/JCO.2005.04.177" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ P Ströbel \n \t\t\t\t\t\t\t\t """ 1 => """ R Bargou \n \t\t\t\t\t\t\t\t """ 2 => """ A Wolff \n \t\t\t\t\t\t\t\t """ 3 => """ D Spitzer \n \t\t\t\t\t\t\t\t """ 4 => """ C Manegold \n \t\t\t\t\t\t\t\t """ 5 => """ A Dimitrakopoulou-Strauss \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1038/sj.bjc.6605740" "Revista" => array:8 [ "tituloSerie" => "Br J Cancer" "fecha" => "2010" "volumen" => "103" "numero" => "2" "paginaInicial" => "196" "paginaFinal" => "200" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20571495" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673606690430" "estado" => "S300" "issn" => "01406736" ] ] ] 1 => array:2 [ "doi" => "10.1038/sj.bjc.6605740" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1038/sj.bjc.6605740" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ XF Li \n \t\t\t\t\t\t\t\t """ 1 => """ Q Chen \n \t\t\t\t\t\t\t\t """ 2 => """ WX Huang \n \t\t\t\t\t\t\t\t """ 3 => """ YB Ye \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1007/s12032-008-9100-0" "Revista" => array:7 [ "tituloSerie" => "Med Oncol" "fecha" => "2009" "volumen" => "26" "numero" => "2" "paginaInicial" => "157" "paginaFinal" => "160" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18846437" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1007/s12032-008-9100-0" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1007/s12032-008-9100-0" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ A Rajan \n \t\t\t\t\t\t\t\t """ 1 => """ CA Carter \n \t\t\t\t\t\t\t\t """ 2 => """ A Berman \n \t\t\t\t\t\t\t\t """ 3 => """ L Cao \n \t\t\t\t\t\t\t\t """ 4 => """ RJ Kelly \n \t\t\t\t\t\t\t\t """ 5 => """ A Thomas \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/S1470-2045(13)70596-5" "Revista" => array:7 [ "tituloSerie" => "Lancet Oncol" "fecha" => "2014" "volumen" => "15" "numero" => "2" "paginaInicial" => "191" "paginaFinal" => "200" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24439931" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/S1470-2045(13)70596-5" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/S1470-2045(13)70596-5" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/18075932/0000007000000012/v1_202212011353/S1807593222013059/v1_202212011353/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/18075932/0000007000000012/v1_202212011353/S1807593222013059/v1_202212011353/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222013059?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 7 | 0 | 7 |
| 2024 October | 62 | 33 | 95 |
| 2024 September | 81 | 25 | 106 |
| 2024 August | 62 | 15 | 77 |
| 2024 July | 74 | 28 | 102 |
| 2024 June | 33 | 7 | 40 |
| 2024 May | 62 | 25 | 87 |
| 2024 April | 77 | 14 | 91 |
| 2024 March | 49 | 8 | 57 |
| 2024 February | 78 | 10 | 88 |
| 2024 January | 83 | 17 | 100 |
| 2023 December | 47 | 14 | 61 |
| 2023 November | 33 | 19 | 52 |
| 2023 October | 18 | 16 | 34 |
| 2023 September | 19 | 12 | 31 |
| 2023 August | 6 | 2 | 8 |
| 2023 July | 4 | 9 | 13 |
| 2023 June | 1 | 1 | 2 |
| 2023 April | 2 | 1 | 3 |
| 2023 March | 2 | 0 | 2 |
| 2023 February | 0 | 0 | 0 |
| 2023 January | 0 | 3 | 3 |
| 2022 December | 29 | 1 | 30 |
Show all